Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + bevacizumab + TAS-102 for third-line metastatic colorectal cancer
ChiCTR2400092941Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, bevacizumab and trifluridine + tipiracil in colorectal cancer (CRC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Objective response rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
sintilimabbevacizumabtrifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2400092941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092941.